Aegerion label for Juxtapid looks favorable, says JPMorgan JPMorgan views the label for Aegerion's Juxtapid as favorable and reiterates an Overweight rating on the stock after the FDA approved the drug. The firm upped its price target for shares to $30 from $28.
Aegerion price target lowered to $46 from $66 at Leerink Leerink lowered its price target for Aegerion shares to $46 after its survey of 40 U.S. cardiologists implied a more bearish outlook for Juxtapid once PCSK9s emerge. The firm, however, believes new patient adds are well outpacing Juxtapid discontinuations in the near term. It keeps an Outperform rating on the stock.